Zacks Research Downgrades AtriCure (NASDAQ:ATRC) to Hold

AtriCure (NASDAQ:ATRC) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Canaccord Genuity Group lifted their price target on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Raymond James Financial set a $52.00 price objective on AtriCure in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, AtriCure has a consensus rating of “Moderate Buy” and an average target price of $48.62.

AtriCure Stock Performance

ATRC opened at $48.68 on Monday. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. AtriCure has a 12-month low of $25.36 and a 12-month high of $49.88. The business has a 50 day moving average of $36.67 and a 200-day moving average of $31.97. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of 231.82 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter in the prior year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts expect that AtriCure will post 0.2 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Justin J. Noznesky sold 6,182 shares of AtriCure stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the transaction, the insider owned 100,219 shares of the company’s stock, valued at $3,888,497.20. The trade was a 5.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Maggie Yuen sold 3,500 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the transaction, the director directly owned 14,015 shares in the company, valued at approximately $538,456.30. This represents a 19.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 44,246 shares of company stock worth $1,691,895 in the last quarter. Insiders own 4.00% of the company’s stock.

Institutional Trading of AtriCure

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its stake in AtriCure by 13.7% in the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock worth $21,927,000 after buying an additional 92,830 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of AtriCure during the 2nd quarter valued at $1,744,000. Rice Hall James & Associates LLC purchased a new position in shares of AtriCure in the second quarter worth about $3,755,000. F m Investments LLC purchased a new stake in shares of AtriCure during the fourth quarter valued at approximately $2,872,000. Finally, Vanguard Group Inc. boosted its position in AtriCure by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after buying an additional 62,861 shares during the period. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.